JP2016503295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503295A5 JP2016503295A5 JP2015540250A JP2015540250A JP2016503295A5 JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5 JP 2015540250 A JP2015540250 A JP 2015540250A JP 2015540250 A JP2015540250 A JP 2015540250A JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 230000027455 binding Effects 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 16
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723545P | 2012-11-07 | 2012-11-07 | |
| US61/723,545 | 2012-11-07 | ||
| US201361749610P | 2013-01-07 | 2013-01-07 | |
| US61/749,610 | 2013-01-07 | ||
| US201361886156P | 2013-10-03 | 2013-10-03 | |
| US61/886,156 | 2013-10-03 | ||
| US201361889179P | 2013-10-10 | 2013-10-10 | |
| US61/889,179 | 2013-10-10 | ||
| PCT/IB2013/059786 WO2014072888A1 (en) | 2012-11-07 | 2013-10-30 | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503295A JP2016503295A (ja) | 2016-02-04 |
| JP2016503295A5 true JP2016503295A5 (show.php) | 2016-12-22 |
Family
ID=49955428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540250A Pending JP2016503295A (ja) | 2012-11-07 | 2013-10-30 | 抗ｉｌ−１３受容体アルファ２抗体および抗体−薬物コンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9828428B2 (show.php) |
| EP (1) | EP2916875A1 (show.php) |
| JP (1) | JP2016503295A (show.php) |
| KR (1) | KR101763499B1 (show.php) |
| CN (1) | CN104936621A (show.php) |
| AU (1) | AU2013343111A1 (show.php) |
| CA (1) | CA2890256A1 (show.php) |
| HK (1) | HK1214161A1 (show.php) |
| IL (1) | IL238566A0 (show.php) |
| MX (1) | MX2015005582A (show.php) |
| PE (1) | PE20150891A1 (show.php) |
| PH (1) | PH12015500977A1 (show.php) |
| RU (1) | RU2015116485A (show.php) |
| SG (1) | SG11201503431TA (show.php) |
| WO (1) | WO2014072888A1 (show.php) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US10344090B2 (en) * | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP2017519740A (ja) | 2014-05-28 | 2017-07-20 | アジェンシス，インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
| AU2015266797C1 (en) | 2014-05-29 | 2019-04-04 | Macrogenics, Inc. | Tri-Specific Binding Molecules that specifically bind to multiple Cancer Antigens and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| ES3035137T3 (en) | 2015-02-16 | 2025-08-29 | Lonza Ag | Cl and/or ch1 mutated antibodies for drug conjugation |
| UA126278C2 (uk) * | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| TWI812873B (zh) * | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| WO2017107817A1 (zh) * | 2015-12-21 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| CN108712911A (zh) * | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| SG11201810883TA (en) | 2016-06-07 | 2019-01-30 | Macrogenics Inc | Combination therapy |
| CN108456250B (zh) | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN107880131A (zh) * | 2017-08-14 | 2018-04-06 | 四川大学 | 一种抗IL‑13Rα2和CD3双特异抗体及其应用 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス，インコーポレーテッド | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2019178085A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| EA202091982A1 (ru) * | 2018-03-14 | 2021-06-10 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| JP7232925B2 (ja) * | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| BR112022015656A2 (pt) | 2020-02-21 | 2022-09-27 | Macrogenics Inc | Moléculas de ligação ao cd137, molécula de ligação ao pd-l1, composição farmacêutica, e ácido nucleico |
| KR20230010188A (ko) * | 2020-05-15 | 2023-01-18 | 엘리세라 테라퓨틱스 에이비 | 항-IL13Rα2 항체, 이의 항원 결합 단편 및 용도 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| TW202302641A (zh) * | 2021-02-19 | 2023-01-16 | 大陸商上海齊魯製藥研究中心有限公司 | 針對IL-13Rα2的抗體及其應用 |
| CA3224476A1 (en) | 2021-07-01 | 2023-01-05 | Xiaoyun SHANG | Antigen-binding polypeptide targeting b7h3 and application thereof |
| CN115768445A (zh) * | 2021-07-01 | 2023-03-07 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| JP2025505777A (ja) * | 2022-02-17 | 2025-02-28 | ラノバ メディシンズ デベロップメント カンパニー， リミテッド | 抗ｉｌ－１３ｒａ２モノクローナル抗体およびその使用 |
| EP4577575A1 (en) * | 2022-08-25 | 2025-07-02 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| CN120882864A (zh) * | 2022-09-30 | 2025-10-31 | 国立大学法人 东京大学 | 靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2002017968A2 (en) * | 2000-08-31 | 2002-03-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| WO2008060813A2 (en) | 2006-10-19 | 2008-05-22 | Merck & Co., Inc. | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| CA2666682C (en) | 2006-10-19 | 2014-07-08 | Merck & Co., Inc. | Anti-il-13r.alpha.1 antibodies and their uses thereof |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| CN103096933A (zh) | 2010-07-12 | 2013-05-08 | CovX科技爱尔兰有限公司 | 多功能抗体缀合物 |
| KR101733853B1 (ko) | 2011-11-17 | 2017-05-08 | 화이자 인코포레이티드 | 세포독성 펩티드 및 그의 항체 약물 접합체 |
| US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013105013A1 (en) | 2012-01-09 | 2013-07-18 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
-
2013
- 2013-10-30 AU AU2013343111A patent/AU2013343111A1/en not_active Abandoned
- 2013-10-30 SG SG11201503431TA patent/SG11201503431TA/en unknown
- 2013-10-30 HK HK16102252.1A patent/HK1214161A1/zh unknown
- 2013-10-30 CA CA2890256A patent/CA2890256A1/en not_active Abandoned
- 2013-10-30 RU RU2015116485A patent/RU2015116485A/ru not_active Application Discontinuation
- 2013-10-30 PE PE2015000568A patent/PE20150891A1/es not_active Application Discontinuation
- 2013-10-30 MX MX2015005582A patent/MX2015005582A/es unknown
- 2013-10-30 US US14/439,897 patent/US9828428B2/en active Active
- 2013-10-30 EP EP13820931.7A patent/EP2916875A1/en not_active Withdrawn
- 2013-10-30 JP JP2015540250A patent/JP2016503295A/ja active Pending
- 2013-10-30 WO PCT/IB2013/059786 patent/WO2014072888A1/en not_active Ceased
- 2013-10-30 KR KR1020157011436A patent/KR101763499B1/ko not_active Expired - Fee Related
- 2013-10-30 CN CN201380057103.5A patent/CN104936621A/zh active Pending
-
2015
- 2015-04-30 PH PH12015500977A patent/PH12015500977A1/en unknown
- 2015-04-30 IL IL238566A patent/IL238566A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503295A5 (show.php) | ||
| RU2015116485A (ru) | Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство | |
| JP2020023523A5 (show.php) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP2022512132A (ja) | 抗クローディン抗体及びそれらの使用 | |
| JP2020502271A5 (show.php) | ||
| JP2010535713A5 (show.php) | ||
| JP2019512242A5 (show.php) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| ES2662418T3 (es) | Agentes de unión a TNF mejorados | |
| JP2017186337A5 (show.php) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2018504105A5 (show.php) | ||
| JP2017531028A5 (show.php) | ||
| JP2020511936A5 (show.php) | ||
| JP2008532523A5 (show.php) | ||
| JP2015516985A5 (show.php) | ||
| JP2013502913A5 (show.php) | ||
| JP2009506790A5 (show.php) | ||
| JP2012100677A5 (show.php) | ||
| JP2010511388A5 (show.php) | ||
| JP2009505676A5 (show.php) | ||
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| JP2016523810A5 (show.php) | ||
| JP2017537620A5 (show.php) |